Browse FXYD2

Summary
SymbolFXYD2
NameFXYD domain containing ion transport regulator 2
Aliases MGC12372; ATP1G1; HOMG2; hypomagnesemia 2, renal; ATPase, Na+/K+ transporting, gamma 1 polypeptide; Na(+)/K( ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type III membrane protein
Domain PF02038 ATP1G1/PLM/MAT8 family
Function

May be involved in forming the receptor site for cardiac glycoside binding or may modulate the transport function of the sodium ATPase.

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0002028 regulation of sodium ion transport
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0006813 potassium ion transport
GO:0006814 sodium ion transport
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0010107 potassium ion import
GO:0010248 establishment or maintenance of transmembrane electrochemical gradient
GO:0010959 regulation of metal ion transport
GO:0015672 monovalent inorganic cation transport
GO:0016049 cell growth
GO:0022898 regulation of transmembrane transporter activity
GO:0032409 regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0034762 regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0035637 multicellular organismal signaling
GO:0035725 sodium ion transmembrane transport
GO:0036376 sodium ion export from cell
GO:0044057 regulation of system process
GO:0060047 heart contraction
GO:0061337 cardiac conduction
GO:0071436 sodium ion export
GO:0071804 cellular potassium ion transport
GO:0071805 potassium ion transmembrane transport
GO:0090662 ATP hydrolysis coupled transmembrane transport
GO:0098657 import into cell
GO:0098739 import across plasma membrane
GO:1902305 regulation of sodium ion transmembrane transport
GO:1903522 regulation of blood circulation
GO:1903779 regulation of cardiac conduction
GO:1904062 regulation of cation transmembrane transport
GO:1990573 potassium ion import across plasma membrane
GO:2000649 regulation of sodium ion transmembrane transporter activity
Molecular Function GO:0005216 ion channel activity
GO:0005391 sodium:potassium-exchanging ATPase activity
GO:0008556 potassium-transporting ATPase activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015079 potassium ion transmembrane transporter activity
GO:0015081 sodium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0015399 primary active transmembrane transporter activity
GO:0015405 P-P-bond-hydrolysis-driven transmembrane transporter activity
GO:0015662 ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism
GO:0016247 channel regulator activity
GO:0016820 hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances
GO:0016887 ATPase activity
GO:0017080 sodium channel regulator activity
GO:0019829 cation-transporting ATPase activity
GO:0022803 passive transmembrane transporter activity
GO:0022804 active transmembrane transporter activity
GO:0022838 substrate-specific channel activity
GO:0022853 active ion transmembrane transporter activity
GO:0042623 ATPase activity, coupled
GO:0042625 ATPase coupled ion transmembrane transporter activity
GO:0042626 ATPase activity, coupled to transmembrane movement of substances
GO:0043492 ATPase activity, coupled to movement of substances
GO:0046873 metal ion transmembrane transporter activity
Cellular Component GO:0005890 sodium:potassium-exchanging ATPase complex
GO:0016323 basolateral plasma membrane
GO:0090533 cation-transporting ATPase complex
GO:0098533 ATPase dependent transmembrane transport complex
GO:1902495 transmembrane transporter complex
GO:1904949 ATPase complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG hsa04022 cGMP-PKG signaling pathway
hsa04024 cAMP signaling pathway
hsa04260 Cardiac muscle contraction
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04911 Insulin secretion
hsa04918 Thyroid hormone synthesis
hsa04919 Thyroid hormone signaling pathway
hsa04960 Aldosterone-regulated sodium reabsorption
hsa04961 Endocrine and other factor-regulated calcium reabsorption
hsa04964 Proximal tubule bicarbonate reclamation
hsa04970 Salivary secretion
hsa04972 Pancreatic secretion
hsa04973 Carbohydrate digestion and absorption
hsa04974 Protein digestion and absorption
hsa04976 Bile secretion
hsa04978 Mineral absorption
Reactome R-HSA-5576891: Cardiac conduction
R-HSA-983712: Ion channel transport
R-HSA-5578775: Ion homeostasis
R-HSA-936837: Ion transport by P-type ATPases
R-HSA-397014: Muscle contraction
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolFXYD2
NameFXYD domain containing ion transport regulator 2
Aliases MGC12372; ATP1G1; HOMG2; hypomagnesemia 2, renal; ATPase, Na+/K+ transporting, gamma 1 polypeptide; Na(+)/K( ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FXYD2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolFXYD2
NameFXYD domain containing ion transport regulator 2
Aliases MGC12372; ATP1G1; HOMG2; hypomagnesemia 2, renal; ATPase, Na+/K+ transporting, gamma 1 polypeptide; Na(+)/K( ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FXYD2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFXYD2
NameFXYD domain containing ion transport regulator 2
Aliases MGC12372; ATP1G1; HOMG2; hypomagnesemia 2, renal; ATPase, Na+/K+ transporting, gamma 1 polypeptide; Na(+)/K( ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FXYD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3530.423
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2510.738
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.80.189
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.90.208
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.2710.381
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4270.799
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.4250.675
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-3.5390.485
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-1.1240.00235
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FXYD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFXYD2
NameFXYD domain containing ion transport regulator 2
Aliases MGC12372; ATP1G1; HOMG2; hypomagnesemia 2, renal; ATPase, Na+/K+ transporting, gamma 1 polypeptide; Na(+)/K( ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FXYD2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFXYD2
NameFXYD domain containing ion transport regulator 2
Aliases MGC12372; ATP1G1; HOMG2; hypomagnesemia 2, renal; ATPase, Na+/K+ transporting, gamma 1 polypeptide; Na(+)/K( ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FXYD2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FXYD2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFXYD2
NameFXYD domain containing ion transport regulator 2
Aliases MGC12372; ATP1G1; HOMG2; hypomagnesemia 2, renal; ATPase, Na+/K+ transporting, gamma 1 polypeptide; Na(+)/K( ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FXYD2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFXYD2
NameFXYD domain containing ion transport regulator 2
Aliases MGC12372; ATP1G1; HOMG2; hypomagnesemia 2, renal; ATPase, Na+/K+ transporting, gamma 1 polypeptide; Na(+)/K( ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FXYD2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFXYD2
NameFXYD domain containing ion transport regulator 2
Aliases MGC12372; ATP1G1; HOMG2; hypomagnesemia 2, renal; ATPase, Na+/K+ transporting, gamma 1 polypeptide; Na(+)/K( ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FXYD2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFXYD2
NameFXYD domain containing ion transport regulator 2
Aliases MGC12372; ATP1G1; HOMG2; hypomagnesemia 2, renal; ATPase, Na+/K+ transporting, gamma 1 polypeptide; Na(+)/K( ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FXYD2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FXYD2.
ID Name Drug Type Targets #Targets
DB00606CyclothiazideSmall MoleculeCA1, CA2, CA4, FXYD2, SFRP45
DB11590ThimerosalSmall MoleculeFXYD2, MTR, SLC7A113